Preparation of purified lymphoma cells suitable for therapy

References

• Gilboa E. The makings of a tumor rejection antigen. Immunio 1999;11:263— 70.
   Google Scholar
• Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients withB-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52— 8.
   PubMed Web of Science ®Google Scholar
• Hsu FJ, Caspar CB, Czerwinski D et al. Tumor-specific idiotypevaccines in the treatment of patients with B-cell lymphoma — long-term results of a clinical trial. Blood 1997;89:3129— 35.
   PubMed Web of Science ®Google Scholar
• Timmerman JM, Czerwinski DK, Davis TA et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002;99:1517–26.
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunio 1999;10:673–9.
   PubMed Web of Science ®Google Scholar
• Minev B, Hipp J, Firat H et al. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci USA 2000;97:4796–801.
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Schultze JL, Anderson KS et al. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Res 2001;61:8366— 70.
   Google Scholar
• Scardino A, Gross DA, Alves P et al. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. 7 Immunol 2002;168: 5900–6.
   Google Scholar
• Khong HT, Restifo NP. Natural selection of rumor variants in the generation of 'tumor escape' phenotypes. Nat Immunol 2002;3:999— 1005.
   Google Scholar
• Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998;392:86–9.
   Google Scholar
• Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. 7 Exp Med 2002;195:125— 33.
   Google Scholar
• Heath WR, Carbone FR. Cross-presentation in viral immunity and self-tolerance. Nat Rev Immunol 2001;1:126— 34.
   Google Scholar
• Kurts C, Miller JF, Subramaniam RM et al. Major histocompat-ibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. y Exp Med 1998;188:409— 14.
   Google Scholar
• Nouri-Shirazi M, Banchereau J, Bell D et al. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. y Immunol 2000;165:3797–803.
   Google Scholar
• Berard F', Blanco P, Davoust J et al. Cross-priming of naive CD8T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. y Exp Med 2000;192: 1535–44.
   Google Scholar
• Subklewe M, Paludan C, Tsang ML et al. Dendritic cells cross-present latency gene products from Epstein— Barr virus-trans-formed B cells and expand tumor-reactive CD8( ) killer T cells. yExp Med 2001;193:405–11.
   PubMed Web of Science ®Google Scholar
• Chaperot L, Chokri M, Jacob MC et al. Differentiation of antigen-presenting cells (dendritic cells and macrophages) for therapeutic application in patients with lymphoma. Leukemia 2000;14:1667— 77.
   Google Scholar
• Stainer CJ, Miflin G, Anderson S et al. A comparison of two different systems for CD34± selection of autologous or allogeneic PBSC collections. y Hematother 1998;7:375–83.
   PubMedGoogle Scholar
• Urbano-Ispizua A, Solano C, Brunet S, et al. Allogeneic transplantation of purified CD34± cells from peripheral blood: Spanish experience of 62 cases. [Spanish Group of allo-PBT.] Bone Marrow Transplant 1998;21 Suppl 3:S71–74.
   Google Scholar
• Hohaus S, Pforsich M, Murea S et al. Immunomagnetic selection of CD34± peripheral blood stem cells for autografting in patients with breast cancer. Br y Haematol 1997;97:881— 8.
   Google Scholar
• Plumas J, Jacob MC, Chaperot L et al. Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis. Blood 1998;91:2875 — 85.
   Google Scholar
• Fadok VA, Bratton DL, Henson PM. Phagocyte receptors for apoptotic cells: recognition, uptake, and consequences. y Clin Invest 2001;108:957–62.
   Google Scholar
• Shacter E, Williams JA, Hinson RM et al. Oxidative stress interferes with cancer chemotherapy: inhibition of lymphoma cell apoptosis and phagocytosis. Blood 2000;96:307–13.
   PubMed Web of Science ®Google Scholar
• Anderson HA, Englert R, Gursel I, Shacter E. Oxidative stress inhibits the phagocytosis of apoptotic cells that have externalized phosphatidylserine. Cell Death Differ 2002;9:616–25.
   PubMedGoogle Scholar
• Manches 0, Lui G, Chaperot L et al. In vitro mechanisms of action of riruximab on primary non-Hodgkin lymphomas. Blood 2003;101:949— 54.
   Google Scholar
• Selenko N, Maidic 0, Draxier S et al. CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. Leukemia 2001;15: 1619–26.
   Google Scholar
• Voll RE, Herrmann M, Roth EA et al. Immunosuppressive effects of apoptotic cells. Nature 1997;390:350–1.
   PubMed Web of Science ®Google Scholar
• Fadok VA, Bratton DL, Konowal A et al. Macrophages that haveingested apoptotic cells in vitro inhibit proinflammatory cyto-kine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAE 7 Clin Invest 1998;101: 890–8.
   Google Scholar